» Articles » PMID: 15927260

Quinoline Antimalarials Decrease the Rate of Beta-hematin Formation

Overview
Journal J Inorg Biochem
Specialty Biochemistry
Date 2005 Jun 2
PMID 15927260
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The strength of inhibition of beta-hematin (synthetic hemozoin or malaria pigment) formation by the quinoline antimalarial drugs chloroquine, amodiaquine, quinidine and quinine has been investigated as a function of incubation time. In the assay used, beta-hematin formation was brought about using 4.5M acetate, pH 4.5 at 60 degrees C. Unreacted hematin was detected by formation of a spectroscopically distinct low spin pyridine complex. Although, these drugs inhibit beta-hematin formation when relatively short incubation times are used, it was found that beta-hematin eventually forms with longer incubation periods (<8h for chloroquine and >8h for quinine). This conclusion was supported by both infrared and X-ray powder diffraction observations. It was further found that the IC(50) for inhibition of beta-hematin formation increases markedly with increasing incubation times in the case of the 4-aminoquinolines chloroquine and amodiaquine. By contrast, in the presence of the quinoline methanols quinine and quinidine the IC(50) values increase much more slowly. This results in a partial reversal of the order of inhibition strengths at longer incubation times. Scanning electron microscopy indicates that beta-hematin crystals formed in the presence of chloroquine are more uniform in both size and shape than those formed in the absence of the drug, with the external morphology of these crystallites being markedly altered. The findings suggest that these drugs act by decreasing the rate of hemozoin formation, rather than irreversibly blocking its formation. This model can also explain the observation of a sigmoidal dependence of beta-hematin inhibition on drug concentration.

Citing Articles

Comprehensive Metabolomics Profiling and Bioactivity Study of (Awsaj) Extracts with Particular Emphasis on Potential Anti-Malarial Properties.

Al-Nemi R, Akkawi M, Sawalha K, Kusumastuti S, Nuralih , Kusumaningrum S Metabolites. 2025; 15(2).

PMID: 39997709 PMC: 11857410. DOI: 10.3390/metabo15020084.


Antimalarial and antioxidant activities of novel artesunate-ellagic acid hybrid compound and .

Ishola A, Adebayo J, Ceravolo I, Tijjani H, Bento E, Goulart H Front Pharmacol. 2024; 15:1192659.

PMID: 38957387 PMC: 11217523. DOI: 10.3389/fphar.2024.1192659.


Evaluation of Antimalarial Activity of Ethanolic Extract of .: An and an Approach.

Nwonuma C, Balogun E, Gyebi G J Evid Based Integr Med. 2023; 28:2515690X231165104.

PMID: 37019435 PMC: 10084581. DOI: 10.1177/2515690X231165104.


Antiparasitic Activities of Compounds Isolated from Strain Discovered in Northcentral Nigeria.

Diyaolu O, Preet G, Fagbemi A, Annang F, Perez-Moreno G, Bosch-Navarrete C Antibiotics (Basel). 2023; 12(1).

PMID: 36671310 PMC: 9854968. DOI: 10.3390/antibiotics12010109.


Evaluation of blood cell count parameters as predictors of treatment failure of malaria in Angola: An observational study.

Sacomboio E, Dos Santos Sebastiao C, Salvador S, Joao J, Bapolo D, Francisco N PLoS One. 2022; 17(5):e0267671.

PMID: 35511769 PMC: 9070872. DOI: 10.1371/journal.pone.0267671.